Elite/Pliva sign generic anti-infective deal

Elite Pharmaceuticals says that it has entered into a product development and licensing deal with Pliva, the USA-based subsidiary of the Croatian specialty generics firm of the same name, which relates to a controlled-release anti-infective formulated by the former company.

According to the group this, as yet undisclosed, anti-infective had a US generic market volume of around $90.0 million in 2004.

Under the terms of the deal, Elite is responsible for manufacturing and Pliva will market and sell the product. Development costs will be paid by both companies and the profits will be shared equally.